The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer

Reviews on Recent Clinical Trials

Volumn 3, Issue 3, 2008, Pages 217-227

  Rossi, Antonio ^a   Bria, Emilio ^b   Maione, Paolo ^a   Palazzolo, Giovanni ^c   Falanga, Marzia ^a   Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c ULSS 15   (Italy)

Author keywords

Cetuximab; EGFR; Matuzumab; Monoclonal antibodies; NSCLC; Panimmumab

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; MATUZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CH806; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NAVELBINE; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PEMETREXED; PLATINUM DERIVATIVE; THERACIM HR 3; UNCLASSIFIED DRUG; VANDETANIB; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ADJUVANT THERAPY; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CARDIOPULMONARY ARREST; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRY SKIN; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; HEAD AND NECK CANCER; HUMAN; HYPOMAGNESEMIA; INFECTION; LETHARGY; LEUKOPENIA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALAISE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PARONYCHIA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; DRUG ANTAGONISM; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOLOGIC FACTORS; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 54049134068     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488708785700276     Document Type: Article

References (81)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-53.
3. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Haematol 1995; 19: 183-232.
4. Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 1996; 7: 133-41.
5. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-12.
6. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003; 10: 1-21.
7. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
8. Kurie JM, Shin HJ, Lee JS, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996; 2: 1787-93.
9. Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993; 68: 162-5.
10. Volm M, Koomagi R, Mattern J, Efferth T. Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients. Clin Cancer Res 2002; 8: 1843-8.
11. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3: 515-22.
12. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7: 1850-55.
13. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20(18 Suppl): 1S-3S.
14. Ciardiello F, Tortora G. Anti+epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investig Drugs 2002; 11: 755-68.
15. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-99.
16. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003; 95: 851-67.
17. Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Expert Opin Biol Ther 2001; 1: 1-14.
18. Humblet Y. Cetuximab: an IgG1 monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin Pharmacother 2004; 5: 1621-33.
19. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904-14.
20. Hanna N, Lilenbaum R, Ansari R, et al. Phase II trial of cetuximab in patients with previously treated non-small cell lung cancer. J Clin Oncol 2006; 24: 5253-8.
21. Kim ES, Mauer AM, Tran HT, et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, incombination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report Proc Am Soc Clin Oncol 2003; 22: 642 (abstr 2581).
22. Buosi R, Gatti A, Carnio S, Sponghini A, Olympios C, Alabiso O. Second line therapy with cetuximab in NSCLC. J Clin Oncol 2006; 24(18S): 678s (abstr 17145).
23. Jalal S, Waterhouse D, Edelmnan M, et al. Pemetrexed plus cetuximab in patients (pts) with recurrent non-small cell lung cancer (NSCLC): a phase I-IIa dose-ranging study from the Hoosier Oncology Group. J Clin Oncol 2007; 25(18S): 433s (abstr 7698).
24. Bradford DS, Socinski MA, LaRocca RV, Hensing TA, Bordoni RE. Phase II trial of carboplatin plus cetuximab for the treatment of stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18S): 684s (abstr 18005).
25. Robert F, Blumenschein G, Herbst RS, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 9089-96.
26. Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small cell lung cancer. J Clin Oncol 2007; 25: 5777-84.
27. Thienelt CD, Bunn PA Jr, Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005; 23: 8786-93.
28. Langer CJ, Ruth K, Borghaei H, et al. Phase II trial of cetuximab (C225) in combination with monthly carboplatin (Cb) and weekly paclitaxel (Pac) in patients with advanced NSCLC: promising early results. J Thor Oncol 2007; 2(suppl 4): S465-7 (abstr PD3-2-8).
29. Belani CP, Ramalingam S, Shreeder M, et al. Phase II study of cetuximab with carboplatin and docetaxel for patients with advanced/ metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18S): 420s (abstr 7643).
30. Saleh MN, Socinski MA, Trent D, et al. Randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/ IV non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(18S): 405s (abstr 7586).
31. Lynch TJ, Patel T, Dreisbach L, et al. A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with taxane/ carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC). J Thor Oncol 2007; 2(suppl 4): S340-1 (abstr B3-03).
32. Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/ vinorelbine alone as first-line treatment therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008; 19: 362-9.
33. Von Pawel J, Park K, Pereira JR, et al. Phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vunorelbine as first-line treatment for patients with epidermal growth factor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC) (FLEX). J Clin Oncol 2006; 24(18S): 391s (abstr. 7109).
34. Herbst RS, Chansky K, Kelly K, et al. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. J Clin Oncol 2007; 25(18S): 395s (abstr 7545).
35. Spigel DR, Greco FA, Burris HA, Yardley DA, Vazquez ER, Hainsworth JD. Docetaxel, gemcitabine, and cetuximab in untreated advanced non-small cell lung cancer. J Thor Oncol 2007; 2 (suppl 4): S740-1 (abstr P3-144).
36. Lilenbaum R, Wang X, Gu L, Kirshner J, Vokes E. Phase II randomized trial of docetaxel plus cetuximab or bortezomib in patients with advanced NSCLC amid performance status (PS) 2- CALGB 30402. J Clin Oncol 2007; 25(185): 408s (abstr 7595).
37. Hughes SR, Liong JL, Miah A, et al. Safety study of induction chemotherapy and synchronous radiotherapy (RT) and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH (cohort I). J Clin Oncol 2007; 25(18S): 686s (abstr 18032).
38. Blumenschein G Jr, Moughan J, Curran W, et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (pts) with stage IIIA/B non-small cell lung cancer (NSCLC): An interim report of the RTOG 0324 trial. J Clin Oncol 2007; 25(18S): 392s (abstr 7531).
39. Coate LE, Cuffe S, McDowell D, et al. Open non-randomised phase II pilot study of neoadjuvant cetuximab in combination with cisplatin and gemcitabine in patients with resectable non small cell lung cancer. J Thor Oncol 2007; 2 (suppl 4): S412 (abstr D7-06).
40. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17-23.
41. Arends R, Yang B, Schwab G, Lockbaum P, Funelas C, Roskos LK. Flexible doses schedules of panitumumab (ABX-EGF) in cancer patients. J Clin Oncol 2005; 23(16S): 214s (abstr 3089).
42. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-64.
43. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: panitumumab (Vectibix ™). Oncologist 2007; 12: 577-83.
44. Weiner LM, Belldegrun A, Crawford J, et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 2008; 14: 502-8.
45. Saadeh CE, Lee HS. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. Ann Pharmacother 2007; 41: 606-13.
46. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 2006; 12 (suppl 14): 4441s-5s.
47. Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004; 22: 175-84.
48. Burger A, Heiss NS, Kreysch HG, et al. The humanized monoclonal anti-EGFR antibody EMD 72000 potently inhibits the growth of EGFR-expressing human tumor xenografts insensitive to chemotherapeutic drugs. Proc Am Ass Cancer Res 2003; 44: 1139 (abstr 5719).
49. Amendt C, Mantel O, Peters M, et al. In vivo activity of humanized monoclonal anti-EGFR antibody EMD72000 in combination with gemcitabine on growth of primary pancreatic tumors and metastases in an orthotopic nude mouse model. Proc Am Ass Cancer Res 2003; 44: 1234 (abstr 6180).
50. Gillies S, Lan Y, Wesolowski J, et al. The role of ADW effector function in the anti-tumor efficacy of anti-EGFR antibodies in a mouse xenograft model. Clin Cancer Res 2003; 9: 127 (abstr B224).
51. Doi T, Ohtsu A, Saijo N, et al. A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody "EMD72000 (Matuzumab)" administered weekly in Japanese patients with advanced solid tumors: safety, PK, and PD results of skin biopsies. J Clin Oncol 2005; 23(16S): 211s (abstr 3077).
52. Kollmannsberger C, Schittenhelm M, Honecker F, et al. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006; 17: 1007-13.
53. Mateo C, Moreno H, Amour K, et al. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: Recovery of antagonistic activity. Immunothechnology 1997; 3: 71-81.
54. Crombet-Ramos T, Rak J, Perez R, et al. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002; 101: 567-75.
55. Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22: 1646-54.
56. Bebb G, Smith C, O'Rourke K, Brade A, Sherman I. Preliminary results of an escalating dose phase I/II clinical trial of the anti EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIB, III or IV NSCLC unsuitable for radical therapy. J Thor Oncol 2007; 2(suppl 8): S617 (abstr P3-023).
57. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994; 91: 7727-31.
58. Panousis C, Rayzman VM, Johns TG, et al. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Br J Cancer 2005; 92: 1069-77.
59. Scott AM, Lee FT, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 2007; 104: 4071-6.
60. Matar P, Rojo F, Cassia R et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): Superiority over single-agent receptor targeting. Clin Cancer Res 2004; 10: 6487-501.
61. Baselga J, Schoffski P, Rojo F, et al. A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(18S): 122s (abstr 3006).
62. Ramalingam S, Forster J, Naret C, et al. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. J Thor Oncol 2008; 3: 258-64.
63. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kunase. Clin Cancer Res 2003; 9: 1546-56.
64. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000; 6: 3739-47.
65. Hoang T, Huang S, Armstrong H, Eickhoff J, Harari P. Tumor response augmentation with combination cetuximab (Erbitux) and bevacizumab (Avastin). Lung Cancer 2005; 49 (suppl 2): S109 (abstr PD-144).
66. Morelli MP, Cascone T, Troiani T, et al. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol 2006; 208: 344-53.
67. Crawford J, Burris H, Stephenson J, et al. Safety and pharmacokinetics (PK) of AMG 706 in combination with panitumumab and gemcitabine-cisplatin in patients (pts) with advanced cancer. J Clin Oncol 2007; 25(188): 616s (abstr 14057).
68. Blumenschein G, Sandler A Jr, O'Rourke T, et al. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/pacitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(18S): 393s (abstr 7119).
69. Saltz L, Kies M, Abbruzzese JL, Azarnia N, Needle M. The presence and intensity of the cetuximab-unduced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003; 22: 204 (abstr 817).
70. Peres-Soler R, Salts L. Cutenous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23: 5235-46.
71. Berlin J, Van Cutsem H, Peeters M, et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials. J Clin Oncol 2007; 25(18S): 196s (abstr 4134).
72. Pippas AW, Lenz HJ, Mayer RJ, et al. Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy. J Clin Oncol 2005; 23(16S): 269s (abstr 3595).
73. Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr). J Clin Oncol 2006; 24(18S): 158s (abstr 3548).
74. Mitchell EP, Hecht JR, Baranda J, et al. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr): An updated analysis. J Clin Oncol 2007; 25(18S): 184s (abstr 4082).
75. Hirsch FR, Bunn PA. Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations? J Clin Oncol 2005; 23: 9044-7.
76. Lilenbaum R, Bonomi P, Ansari R, et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): Final results. J Clin Oncol 2005; 23(16S): 629s (abstr 7036).
77. Mukohara T, Engelman JA, Hanna NH, et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005; 97: 1185-94.
78. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:279-86.
79. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumomab. J Clin Oncol 2007; 25: 3238-45.
80. Langerak AD, Mitchell E, Cheema P, River GL, Shing M. Institutional experience with panitumumab monotherapy in metastatic colorectal cancer (mCRC) patients (pts) intolerant to cetuximab. J Clin Oncol 2007; 25(18S): 631s (abstr 14579).
81. PDQ National Cancer Institute Clinical Trials Database. http://www.cancer.gov/clinical_trials, accessed April 6,2008.